Cytokine correlates of clinical response patterns to infliximab treatment of ankylosing spondylitis

Objective: To identify clinical and immunological markers of response to treatment with infliximab in ankylosing spondylitis (AS). Methods: Baseline and sequential cytokine levels (IL1, TNFα, IFNγ, TGFβ and IL10) were examined after 52 weeks of infliximab treatment 5 mg/kg in 22 patients. Results: A...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of the rheumatic diseases 2004-01, Vol.63 (1), p.84-87
Hauptverfasser:	Stone, M A, Payne, U, Pacheco-Tena, C, Inman, R D
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Analysis of Variance ankylosing spondylitis ANOVA Antibodies, Monoclonal - therapeutic use Antirheumatic Agents - therapeutic use AS Assessment Study ASAS BASDAI BASFI Bath AS Disease Activity Index Bath AS Spondylitis Index Biological and medical sciences Biomarkers - blood C reactive protein C-Reactive Protein - metabolism Concise Report CRP Cytokines Cytokines - blood disease modifying antirheumatic drug Diseases of the osteoarticular system DMARD Drug Monitoring - methods ELISA enzyme linked immunosorbent assay Enzymes erythrocyte sedimentation rate ESR Female Follow-Up Studies Humans IFNγ Immunology Inflammatory joint diseases Infliximab interferon γ interleukin Laboratories Likert scale Male Medical sciences Middle Aged non-steroidal anti-inflammatory drug NSAID Pain Patient Selection Patients PBMC peripheral blood mononuclear cells Polyclonal antibodies Prognosis SpA Spondylitis, Ankylosing - blood Spondylitis, Ankylosing - drug therapy Spondylitis, Ankylosing - immunology spondyloarthropathy Statistical analysis Studies TGFβ TNFα transforming growth factor β Treatment Outcome Tumor Necrosis Factor-alpha - metabolism Tumor necrosis factor-TNF tumour necrosis factor α Variance analysis VAS visual analogue scale
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Objective: To identify clinical and immunological markers of response to treatment with infliximab in ankylosing spondylitis (AS). Methods: Baseline and sequential cytokine levels (IL1, TNFα, IFNγ, TGFβ and IL10) were examined after 52 weeks of infliximab treatment 5 mg/kg in 22 patients. Results: At week 52, 18 patients were responders and four non-responders according to ASAS group criteria. Clinical measures of disease activity between the two groups at baseline were similar, apart from a trend towards longer disease duration in non-responders (p = 0.08). Baseline CRP and TNFα levels were higher in responders than non-responders (p
ISSN:	0003-4967 1468-2060
DOI:	10.1136/ard.2003.006916